Quick Take
Cortexyme (CRTX) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing a new potential therapeutic for the treatment of Alzheimer’s disease.
CRTX has had positive safety trial results and intriguing post-treatment markers for Phase 1 trial patients.
I’ll provide an update when we learn more IPO details.
Company & Technology
San Francisco, California-based Cortexyme was founded in 2012 to develop a new upstream therapy for Alzheimer’s disease [AD].
Management is headed by Founder, President and CEO